ANTHERA PHARMACEUTICALS

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2004-01-01

Employees: -

Market Cap: -

Website: http://www.anthera.com

Clinical Trials

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

Phase 3

Conditions: Exocrine Pancreatic Insufficiency
Cystic Fibrosis

Interventions: Drug: Liprotamase
Drug: porcine PERT

First Posted Date: 2017-02-13

Last Posted Date: 2018-03-08

Lead Sponsor: Anthera Pharmaceuticals

Target Recruit Count: 140

Registration Number: NCT03051490

Locations: 🇺🇸
Investigator Site #103, Cleveland, Ohio, United States
🇭🇺
Investigator Site 304, Mosdós, Somogy County, Hungary
🇭🇺
Investigator Site 307, Budapest, Hungary

and more 47 locations

EASY: Extended Access to Sollpura Over Years

Phase 4

Completed

Conditions: Exocrine Pancreatic Insufficiency
Cystic Fibrosis

Interventions: Drug: Liprotamase

First Posted Date: 2016-07-06

Last Posted Date: 2018-05-17

Lead Sponsor: Anthera Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT02823964

Locations: 🇺🇸
Investigator Site 134, Jackson, Mississippi, United States
🇺🇸
Investigator Site 121, Burlington, Vermont, United States
🇭🇺
Investigator Site 304, Mosdos, Somogy County, Hungary

and more 12 locations

SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis

Phase 3

Completed

Conditions: Exocrine Pancreatic Insufficiency
Cystic Fibrosis

Interventions: Drug: Liprotamase Powder for Oral Solution

First Posted Date: 2016-04-12

Last Posted Date: 2018-05-11

Lead Sponsor: Anthera Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT02734810

Locations: 🇺🇸
Investigator Site 114, Aurora, Colorado, United States
🇺🇸
Investigator Site 130, Miami, Florida, United States
🇺🇸
Investigator Site 122, Louisville, Kentucky, United States

and more 18 locations

CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Phase 3

Terminated

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Placebo
Drug: Blisibimod

First Posted Date: 2015-08-04

Last Posted Date: 2017-05-23

Lead Sponsor: Anthera Pharmaceuticals

Target Recruit Count: 3

Registration Number: NCT02514967

Locations: 🇬🇪
Investigator Site 004, Tbilisi, Georgia
🇬🇪
Investigator Site 002, Tbilisi, Georgia
🇬🇪
Investigator Site 001, Tbilisi, Georgia

SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis

Phase 3

Completed

Conditions: Exocrine Pancreatic Insufficiency
Cystic Fibrosis

Interventions: Drug: Liprotamase
Drug: porcine (pig) PERT

First Posted Date: 2014-10-31

Last Posted Date: 2018-08-14

Lead Sponsor: Anthera Pharmaceuticals

Target Recruit Count: 128

Registration Number: NCT02279498

Locations: 🇺🇸
Investigator Site 132, Portland, Maine, United States
🇺🇸
Investigator Site 115, Pittsburgh, Pennsylvania, United States
🇺🇸
Investigator Site 120, Gainesville, Florida, United States

and more 51 locations

CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Phase 3

Withdrawn

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Placebo
Drug: Blisibimod

First Posted Date: 2014-02-28

Last Posted Date: 2015-08-13

Lead Sponsor: Anthera Pharmaceuticals

Registration Number: NCT02074020

BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration

Phase 2

Completed

Conditions: IgA Nephropathy

Interventions: Drug: Blisibimod
Drug: Placebo

First Posted Date: 2014-02-14

Last Posted Date: 2017-09-18

Lead Sponsor: Anthera Pharmaceuticals

Target Recruit Count: 57

Registration Number: NCT02062684

Locations: 🇵🇭
Investigator Site 402, Quezon City, Philippines
🇵🇭
Investigator Site 401, Quezon City, Philippines
🇨🇳
Investigator Site 704, Changhua, Taiwan

and more 20 locations

BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

Phase 3

Withdrawn

Conditions: IgA Nephropathy

Interventions: Drug: Placebo
Drug: Blisibimod

First Posted Date: 2014-02-03

Last Posted Date: 2015-07-30

Lead Sponsor: Anthera Pharmaceuticals

Registration Number: NCT02052219

MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP

Phase 2

Withdrawn

Conditions: Immune Thrombocytopenic Purpura
Idiopathic Thrombocytopenic Purpura

Interventions: Biological: Blisibimod
Other: Placebo

First Posted Date: 2012-06-01

Last Posted Date: 2015-07-30

Lead Sponsor: Anthera Pharmaceuticals

Registration Number: NCT01609452

BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis

Phase 2

Withdrawn

Conditions: Microscopic Polyangiitis
Granulomatosis With Polyangiitis

Interventions: Drug: Blisibimod
Drug: Placebo

First Posted Date: 2012-05-15

Last Posted Date: 2015-07-30

Lead Sponsor: Anthera Pharmaceuticals

Registration Number: NCT01598857

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy